Upstream Bio, founded in 2021, is a biotechnology company with the goal of advancing the medical field through genetic technologies and computational methods. Their work predominantly revolves around aiming to develop novel therapeutics for challenging diseases, pushing boundaries in personalized medicine and genomics, and striving for breakthroughs that could significantly enhance human health and lifespan.

Register for Details

For more details on financing and valuation of private companies similar to Upstream Bio before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Upstream Bio

To invest in Upstream Bio pre-IPO

Can you invest in Upstream Bio pre-IPO?

You may invest in Upstream Bio as it is a public company listed on the NASDAQ with ticker UPB. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Upstream Bio before it goes public?

You can no longer sell shares of Upstream Bio on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Upstream Bio shares?

Forge can no longer determine the value of Upstream Bio shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Upstream Bio a publicly traded company?

Upstream Bio became a public company following its IPO on 10/11/2024 and is now traded on the NASDAQ under the ticker UPB.

To learn more about Upstream Bio potential IPO

Will Upstream Bio go IPO?

Upstream Bio became a public company following its IPO on 10/11/2024 and is now traded on the NASDAQ under the ticker UPB.

What is Upstream Bio’s IPO price?

The IPO price of Upstream Bio is not currently available.

When was Upstream Bio founded?

Upstream Bio was founded in 2021.

What is Upstream Bio funding to date?

Upstream Bio has raised $800MM to date.

Who are Upstream Bio’s major investors?

Hbm Healthcare Investments
Orbimed
Tcg X
Venrock Healthcare Capital Partners
Samsara Biocapital
Bain Capital Life Sciences
Omega Funds
Enavate Sciences
Maruho Company
Wellington Management
Altshuler Shaham Provident Funds
Access Biotechnology
Altshuler Shaham Provident Funds Ltd
Decheng Capital

Upstream Bio Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/08/2023 Series B $200MM $xx.xx $676.16MM Access Biotechnology, Altshuler Shaham Provident Funds Ltd, Bain Capital Life Sciences, Decheng Capital, Enavate Sciences, Hbm Healthcare Investments, Omega Funds, Orbimed, Samsara Biocapital, Tcg X, Venrock Healthcare Capital Partners, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
11,764,693
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Altshuler Shaham Provident Funds Ltd, Bain Capital Life Sciences, Decheng Capital, Enavate Sciences, Hbm Healthcare Investments, Omega Funds, Orbimed, Samsara Biocapital, Tcg X, Venrock Healthcare Capital Partners, Wellington Management
06/02/2022 Series A $200MM $xx.xx $272MM Access Biotechnology, Altshuler Shaham Provident Funds, Decheng Capital, Hbm Healthcare Investments, Maruho Company, Omega Funds, Orbimed, Samsara Biocapital, Tcg X
Price per Share
$xx.xx
Shares Outstanding
20,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Altshuler Shaham Provident Funds, Decheng Capital, Hbm Healthcare Investments, Maruho Company, Omega Funds, Orbimed, Samsara Biocapital, Tcg X
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.